ArticleHuman vaccines & immunotherapeutics2019
Epidemiologic challenges in norovirus vaccine development.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Management of Norovirus Infection in Solid Organ Transplant Recipients: A Scoping Review.Transplantation direct · 2026Article
- Health Care Costs Associated With Norovirus at the Veterans Health Administration.JAMA network open · 2025Article
- Molecular Characterization of Noroviruses Causing Acute Gastroenteritis Outbreaks among US Military Recruits, 2013-2023.Emerging infectious diseases · 2024Article
- Prevalence, Clinical Features, and Genotypes of Norovirus-Associated Diarrhea in Wuxi, China, 2013-2020.The American journal of tropical medicine and hygiene · 2024Article
- In Vitro Antiviral and Virucidal Activity of Ozone against Feline Calicivirus.Animals : an open access journal from MDPI · 2024Article
- Engineered Yeast Displaying Specific Norovirus-Binding Nanobodies for the Concentration and Detection of Human Norovirus in Food Matrix.Journal of agricultural and food chemistry · 2023Article
- Amplicon-Based High-Throughput Sequencing Method for Genotypic Characterization of Norovirus in Oysters.Applied and environmental microbiology · 2023Article
- Serological surveillance of GI norovirus reveals persistence of blockade antibody in a Jidong community-based prospective cohort, 2014-2018.Frontiers in cellular and infection microbiology · 2023Article
- Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection.Viruses · 2022Article
- Challenges for Vaccinologists in the First Half of the Twenty-First Century.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Norovirus Vaccines: Current Clinical Development and Challenges.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Article
- Review
- Advances in Human Norovirus Vaccine Research.Vaccines · 2021Review
- Acute Gastroenteritis Disease Burden in Infants With Medical Risk Conditions in the Netherlands.The Pediatric infectious disease journal · 2021Article
- Fucoidan But Not 2'-Fucosyllactose Inhibits Human Norovirus Replication in Zebrafish Larvae.Viruses · 2021Article
- Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting.American journal of preventive medicine · 2021Article
- Temporal and Genotypic Associations of Sporadic Norovirus Gastroenteritis and Reported Norovirus Outbreaks in Middle Tennessee, 2012-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Understanding Pediatric Norovirus Epidemiology: A Decade of Study among Ghanaian Children.Viruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,000 hospitalizations, and 570-800 deaths annually. Through direct costs and loss of productivity, norovirus disease cost the US economy more than $5.5 billion annually. Due to the lack of available therapies to treat norovirus infections and their highly infectious nature, preventing norovirus illness through vaccination is an appealing strategy. Currently, several norovirus vaccines are in development, including five vaccines in preclinical trials, an oral monovalent vaccine (Vaxart, Inc.) that recently completed a phase IB clinical trial, and a bivalent intramuscular vaccine (Takeda Pharmaceutical Company Limited) in a phase IIB clinical trial. However, no norovirus vaccines are currently available on the market. In this commentary we aim to describe some of the barriers faced in norovirus vaccine development, particularly focusing on vaccine effectiveness and defining the target population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.